Lutetium Lu 177-Edotreotide

Phase 1Radiopharmaceutical

Lutetium Lu 177-Edotreotide is one of 4 small molecule programs targeting Somatostatin Receptor Positive. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Somatostatin Receptor PositiveRecruiting

Somatostatin Receptor PositivePhase 1

Recruiting

Competition

Competitive Landscape

3 competitors in Somatostatin Receptor Positive

#DrugCompanyPhaseTrials

Lutetium Lu 177-Edotreotide

IITM Solucin GmbH

Phase 1

1 2

[203pb]vmt-Alpha-NET

NNational Cancer Institute (NCI)

Preclinical

1 3

[212pb]vmt-Alpha-NET

NNational Cancer Institute (NCI)

Preclinical

1 4

VMT-Alpha-NET

NNational Cancer Institute (NCI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2034

Phase 1Recruiting

Somatostatin Receptor Positive

NCT06441331

Clinical

Trials by Indication[1]

Somatostatin Receptor Positive1 trial

A Multicenter, Open-label, Interventional Phase I Trial to Determine the Dose and Evaluate the Pharmacokinetics (PK) and Safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as Monotherapy or Following Standard of Care (SoC) for the Treatment of Somatostatin Receptor-positive Tumors in the Pediatric Population (KinLET).

Recruiting·IITM Solucin GmbH·Phase 1·NCT06441331·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lutetium Lu 177-Edotreotide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lutetium Lu 177-Edotreotide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lutetium Lu 177-Edotreotide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ITM Solucin GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Phase 1[1]
Company: IITM Solucin GmbH

Lutetium Lu 177-Edotreotide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2034

Trials by Indication[1]

Somatostatin Receptor Positive1 trial

References

Drug Info

Quick Facts

Related News